

 <p>ALPHAFORM</p> <p>Aktiengesellschaft</p>	<div data-bbox="759 353 1050 454"></div> <div data-bbox="759 477 1050 577"></div> <div data-bbox="759 600 1050 701"></div> <div data-bbox="759 723 1050 813">1st Quarter</div>	<p>2009</p>
--	---	--------------------

Alphaform shaped by economic downturn in first quarter of 2008

The key figures for the first quarter of the 2009 financial year are as follows:

- At €5,508 thousand, revenues in the first quarter of 2009 were up 4.4% on the same quarter of the previous year (€5,274 thousand).
- The Group's booked business as of 31 March 2009 amounted to €1.9 million (31 March 2008: €1.4 million not including MediMet).
- EBITDA was down from €566 thousand in the same quarter of the previous year to minus €228 thousand in the first quarter of 2009.
- Consolidated net income after interest and taxes declined by €1,193 thousand in the first quarter of 2009 to minus €872 thousand after a positive figure of €321 thousand in the first quarter of 2008.
- Earnings per share were down in the first quarter from €0.06 in 2008 to minus €0.16 in 2009.
- Cash flow from operating activities in the first three months of the financial year was down €5,215 thousand on the previous year's figure at minus €4,822 thousand (€393 thousand).
- The number of employees as of 31 March 2009 in full time equivalents was 210 (31 March 2008: 141).

Key figures of the Alphaform Group

€ thousand, except employees and earnings per share	1st quarter		
	2009	2008	Change (%)
Revenues	5,508	5,274	4.4
EBITDA	-228	566	N/A
Operating result	-862	201	N/A
Earnings after taxes	-872	321	N/A
Earnings per share	-0.16	0.06	N/A
Equity as of 31 March (31 December 2008)	18,343	19,223	-4.6
Total assets as of 31 March (31 December 2008)	28,091	27,521	2.1
Equity ratio (%)	65.3	69.8	-6.4
Cash and cash equivalents and current financial instruments as of 31 March (31 December 2008)	1,229	5,226	-76.5
Group employees as of 31 March (FTEs)	210	141	48.9

Interim Group Management Report

Company development/sector overview

The first quarter of the financial year 2009 was dominated by the downturn of the economy as a whole. Throughout the Group, incoming orders were down around 25% on the previous year's level. Our activities with the Formula 1 teams (down around 65%) and the automotive industry (down around 30%) were hit particularly hard. In contrast, the Medical Technology division posted an encouraging performance in its business. MediMet's revenues and orders are up around 10% on the previous year's level (first-time consolidation: December 2008). In line with the overall economic climate, we are assuming that the investment propensity of our customers will remain at a low level in traditional Alphaform business in 2009 with a recovery to follow in the second half of the year.

EBITDA deteriorated significantly compared to the previous year in the first quarter of 2009 and is still slightly below the level of the fourth quarter of 2008. The cost-cutting measures are being introduced from April 2009 and should lead to an improvement in EBITDA in the coming quarters, assuming that the overall economic situation does not grow any worse.

We are assuming a 20% decline in revenues over the year in the Alphaform Group's old business (not including MediMet) and have adjusted our cost structures accordingly. The planning for cost reductions essentially includes headcount measures in the form of redundancies and short-time work, process improvements and savings in procurement. The requirements of headcount measures and the reduction of flexitime and holiday accounts in particular will not start to show an effect until the second quarter. The total planned savings volume for the 2009 financial year is around €2.5 million.

At 63.7%, the gross profit was down around 3.0% on the previous year's level. However, the inclusion in consolidation of MediMet resulted in a change in our business model. In the first quarter, medical implants and instruments accounted for around a third of our revenue.

In the coming years, we are hoping to take Alphaform's business activities to the next level in terms of revenues and income. To achieve sustainable success on the capital markets, Alphaform must significantly increase its current revenue volume and ensure profitability in the long term. The change in strategy in 2008 is already having a positive effect in the present economic crisis: Without our new positioning in the medical technologies market, our dependence on economy-sensitive markets would be substantially greater.

Our business development is focused on further extending our established positioning in medical technology and expansion in the aerospace area. We intend to go forward with our commitment to our Eastern European production locations. No major investments are planned in times of economic crisis. To support our positioning in medical technology and aerospace we will also further expand our metals competence. We are pursuing an international buy and build strategy for both of these goals.

Net assets, financial position and results of operations

Revenue development and order situation

As against the same period of the previous year, consolidated revenues increased by 4.4% to €5,508 thousand after €5,274 in the first three months of 2008. It should be noted that the Alphaform Group did not include MediMet GmbH in the first quarter of 2008.

Booked business amounted to €1.9 million at the end of the first quarter of 2009. The order backlog was therefore up 35.7% as against the same period of the previous year (31 March 2008: €1.4 million not including MediMet GmbH).

Cost of materials and gross profit

At 63.7%, the gross profit generated in the first three months of 2009 was down 3.0 percentage points on the 2008 figure of 66.7%.

The cost of materials rose by €145 thousand year-on-year in the first three months of 2009 from €1,938 thousand to €2,083 thousand. In particular, this increase reflects the growing complexity of orders in core rapid prototyping business, the rising pressure on margins and the growth in services purchased from our Eastern European partners.

Earnings situation

Earnings in the Alphaform Group slumped in the first three months of 2009 as against the same period of the previous year. As of 31 March 2009, they deteriorated by €1,193 thousand to a loss of €872 thousand from a profit of €321 thousand as of 31 March 2008. Around €286 thousand of the loss of €872 thousand related to the write-downs as part of the MediMet purchase price allocation.

Staff costs

Staff costs rose by €702 thousand year-on-year in the first the months of 2009, an increase of 41.0%. 60% of this increase related to the addition of MediMet GmbH.

Depreciation and amortisation expenses

Depreciation and amortisation expenses rose strongly in the first three months of 2008 compared to the same quarter of the previous year. Depreciation and amortisation expense amounted to €634 thousand in 2009, 74% higher than the 2008 figure of €365 thousand. The main reason for this was not only the additional write-downs for MediMet GmbH but rather amortisation of €286 thousand incurred as part of MediMet's purchase price allocation.

Other operating expenses

Other operating expenses were €83 thousand higher year-on-year in the first three months of 2009 at €1,323 thousand after €1,240 thousand in the first quarter of 2008.

Financing and cash flow

The consolidated cash flow statement shows the origin and use of cash flows in the first three months of the 2009 and 2008 financial years. Cash flows are broken down into those from operating activities, investing activities and financing activities.

Cash flow from operating activities in the period from January to March 2009 declined by €5,215 thousand year-on-year to minus €4,822 thousand after the previous year's cash inflow figure of €393 thousand. This was mainly due to transfers of €3,585 thousand to the restricted bank balances in connection with the guarantees provided to former MediMet shareholders for outstanding purchase price components and the €1,500 thousand provided as collateral for the loans extended by DZ Bank at the end of February 2009.

The net cash used in investing activities rose from €501 thousand in the period from January to March 2008 to €1,168 thousand in the same period of 2009. At €1,036 thousand, most of this related to further purchase price payments for the acquisition of MediMet.

In the first three months of 2009, financing activities generated a cash inflow of €1,993 thousand. This includes the €2,500 thousand loans paid by DZ Bank on 27 February 2009.

Cash and cash equivalents and current financial instruments declined by €10,518 thousand year-on-year. As of the reporting date 31 March 2009, cash and cash equivalents amounted to €1,229 thousand as against €11,737 thousand as of 31 March 2008.

Balance sheet

Total assets amounted to €28,091 thousand as of 31 March 2009, a slight increase as against €27,521 thousand as of the 31 December 2008 balance sheet date. The equity ratio was down to 65.3% as of 31 March 2009 after 69.8% as of 31 December 2008.

The biggest changes as against the end of 2008 related to the items restricted bank balances and liabilities to banks. On 9 February 2009, Alphaform AG entered into a loan agreement of €2.5 million with DZ Bank Frankfurt. The loan has a term of five years and bears interest at 2.5% p.a. above one-month EURIBOR. A cap transaction that limits the EURIBOR to 3.5% for the whole term of the loan was concluded to hedge the interest on the loan.

Employees

The Company employed 210 employees (FTEs) as of 31 March 2009. This represents an increase of 48.9% as against the previous year. The Alphaform Group currently employs a total of ten trainees.

The employee structure as of 31 March 2009 and as of 31 March 2008 was as follows:

	1st quarter		Change (%)
	2009	2008	
	Alphaform AG	99	90
Alphaform-Claho GmbH	36	30	20.0
Alphaform RPI Oy, Finland	15	15	0.0
Alphaform Ltd., UK	7	6	16.7
Alphaform-Projekt GmbH	0	0	0.0
MediMet GmbH	53	0	N/A
Total number of employees in the Group	210	141	48.9

Risk report and outlook

The Alphaform Group continues to generate a significant proportion of its revenues through project orders from the automotive industry. This industry in particular is characterised by difficult market prospects for suppliers, increasingly aggressive price competition, stricter development budgets and shorter project deadlines from automotive manufacturers. In addition, the development landscape of the automotive industry as a whole is changing. As it is not always possible for us to predict these developments, they therefore pose a significant risk for the utilisation of our capacity and hence for our earnings. Further risks are described in detail in the Group management report. Please see also the risk report in the 2008 Annual Report.

Outlook

We are forecasting moderate growth at Group level for 2009. The medical technology acquisition will largely compensate the decline in old business. The challenge facing the Company in 2009 is handling the economic crisis. With the ongoing restructuring program, we intend to offset the decline in revenues from old business and are striving for a balanced result of operations in this area. This does not include extraordinary expensed at Group level, such as increased amortisation on the intangible assets of MediMet.

In medical technology we are forecasting stronger growth of 1% as against the previous year and are assuming similar earnings year-on-year. In the coming months, the Company will continue to focus on the integration of MediMet, which has progressed smoothly thus far. Parallel to this, we intend to gradually increase penetration of the orthopaedic market and acquire initial pilot customers for plastics applications from the existing Alphaform portfolio.

Feldkirchen, May 2009

Alphaform AG

The Management Board

Consolidated income statement

In T€, with the exception of earnings per share and number of shares	1 January - 31 March	
	2009	2008
Revenues	5.508	5.274
Changes in inventories	-9	129
Own work capitalised	0	0
Other operating income	94	54
Cost of materials	-2.083	-1.938
Gross profit	3.510	3.519
Personnel expenses	-2.415	-1.713
Depreciation and amortisation costs and other write-offs	-634	-365
Other operating expenses	-1.323	-1.240
Operating result	-862	201
Other interest and similar income	14	123
Interest and similar expenses	-74	-2
Other operating income/expenses	0	0
Result before tax	-922	322
Taxes on income	-40	-1
Deferred taxes	90	0
Other taxes	0	0
Result after tax	-872	321
Allocations of profit or loss		
profit or loss attributable to minority interest	-8	20
Gross profit / loss	-880	341
Profit/loss per share		
Profit/loss per share (basic)	-0,16	0,06
Profit/loss per share (diluted)	-0,16	0,06
Weighted average number of shares outstanding (basic)	5.318.209	5.318.209
Weighted average number of shares outstanding (diluted)	5.318.209	5.318.209

Consolidated balance sheet

T€	31 March 2009	31 December 2008
Assets		
Cash and cash Equivalents	4.814	5.226
free cash	1.229	5.226
restricted cash	3.585	0
Short-term investments	0	0
Trade accounts receivable	4.609	4.323
Inventories	3.531	3.670
Other current assets	715	403
Total current assets	13.669	13.622
Property and equipment, net	5.748	5.975
Intangible assets, net	1.398	1.684
Goodwill, net	7.202	6.166
Deferred Tax asset	42	42
Other non-current assets	32	32
Total noncurrent assets	14.422	13.899
Total Assets	28.091	27.521
T€	31 March 2009	31 December 2008
Liabilities and shareholders' equity		
Common stock, € 1 par value	5.318	5.318
Additional paid-in capital	11.325	11.325
Accumulated other comprehensive loss	49	57
Accumulated profit/loss	1.651	2.523
Total shareholders' equity	18.343	19.223
Noncurrent liabilities		
Liabilities due to banks	2.554	99
Liabilities due to MediMet acquisition (long term)	1.880	1.880
Deferred Tax liabilities	465	555
Current liabilities		
Current finance lease obligations	0	0
Liabilities due to banks	254	715
Trade accounts payable	1.664	2.191
Other provisions/liabilities	2.931	2.858
Total liabilities	9.748	8.298
Total liabilities and shareholders' equity	28.091	27.521
2008 and 2009: 5,318,209 shares per € 1 par value		
2008 and 2009 authorised capital stock € 2,659,104		
2008 and 2009 conditional capital € 531,820		

Consolidated cash flow statement

	1 January - 31 March	
	2009	2008
T€		
Result after taxes	-872	321
Adjustments reconcile net profit/loss to net cash from/used in operating activities		
Depreciation of property, plant and equipment	360	365
Depreciation of intangible assets	286	0
Goodwill amortisation	0	0
Sale of property, plant and equipment at residual value	0	0
Currency translation differences	-9	22
Bad debt allowances	178	-61
Deferred taxes	-90	0
Changes in operating assets and liabilities:		
Trade receivables	-464	371
Inventories	139	-259
Other current assets	-312	37
Restricted cash	-3.585	0
Liabilities	-527	-163
Other provisions and liabilities	74	-240
Net cash from operating activities	-4.822	393
Acquisition of current assets	0	0
Acquisition of property, plant and equipment, excl. finance leases	-173	-501
Proceeds from the sale of property, plant and equipment, excl. finance leases	41	0
Acquisition of subsidiaries	-1.036	0
Net cash used in investing activities	-1.168	-501
New Bank Loans	2.500	0
Principal payments on bank loans	-506	0
Principals payments under finance leases	0	-24
Net cash used in financing activities	1.993	-24
Net reduction in cash and cash equivalents	-3.997	-131
Cash, cash equivalents and short term investments at beginning of period	5.226	11.878
Cash and cash equivalents including short-term investments at the end of the period	1.229	11.747
Additional cash flow statement disclosures		
Cash paid for interest	74	2
Non-cash transactions:		
Property, plant and equipment acquired under finance leases	0	0
Unrealised gains/losses on the revaluation of securities	0	69

Consolidated statement of changes in equity

	Common Stock		Additional paid-in-capital	Accumulated other comprehensive income	Accumulated profit / deficit	Total shareholders' equity
	Number of shares	Amount				
All figures in € thousand except number of shares						
IAS/IFRS shareholders' equity as of December 31, 2007	5.318.209	5.318	11.325	27	3.982	20.652
Result					321	321
Foreign currency translation				20		20
Change in shareholders' equity due to realised gains				0		0
IAS/IFRS shareholders' equity as of March 31, 2008	5.318.209	5.318	11.325	47	4.303	20.993
IAS/IFRS shareholders' equity as of December 31, 2008	5.318.209	5.318	11.325	57	2.523	19.223
Result					(872)	(872)
Foreign currency translation				(8)	0	(8)
Change in shareholders' equity due to realised gains				0		0
IAS/IFRS shareholders' equity as of March 31, 2009	5.318.209	5.318	11.325	49	1.651	18.343

Notes to the consolidated financial statements (abridged)

These consolidated interim financial statements were prepared in accordance with the International Financial Reporting Standards (IFRSs) and IAS 34 Interim Financial Reporting issued by the International Accounting Standards Board (IASB), London, in conjunction with the interpretations issued by the International Financial Reporting Interpretations Committee (IFRIC). They were not audited as in line with section 317 of the German Commercial Code (HGB), nor were they reviewed by an auditor.

Scope of consolidation

The consolidated financial statements include Alphaform AG and all of its associated subsidiaries. There was no change in the group of consolidated companies in the first three months of 2009 as against 31 December 2008.

As of 31 March, the Company held all shares in the following subsidiaries:

- Alphaform-Projekt GmbH, Feldkirchen, Germany 100%
- Alphaform Ltd., Newbury, UK 100%
- Alphaform-Claho GmbH, Garmisch-Partenkirchen, Germany 100%
- Alphaform RPI Oy, Rusko, Finland 100%
- MediMet Precision Casting and Implants Technology GmbH, Germany 100%

Basic accounting policies

The interim financial statements were prepared in accordance with the same accounting policies as the consolidated financial statements for the year ended 31 December 2008.

The recommendations of Deutsche Börse on quarterly reporting by companies listed in the Prime Standard also apply.

The same principles of consolidation were applied in preparing this interim financial report and calculating comparative figures as for the 2008 consolidated financial statements.

Segment reporting

A business segment is a distinguishable component of a group that is engaged in providing products or services and that is subject to risks and returns that are different from those of other business segments.

Segment information is provided on the Group's business and geographical segments. The basis for the primary segment reporting format is the Group's management structure and its internal financial reporting system. Segment earnings contain components that are directly attributable to the individual segment or that can be reasonably allocated to the segments.

The Group primarily consists of the following two geographical segments:

Central Europe

The Central Europe region comprises the companies Alphaform AG, Feldkirchen; Alphaform-Claho GmbH, Garmisch-Partenkirchen, Alphaform-Projekt GmbH, Feldkirchen, and MediMet Precision Casting and Implants Technology GmbH, Stade.

Northern Europe

The Northern Europe business segment comprises Alphaform RPI Oy, Finland, and Alphaform Ltd, United Kingdom.

Business segments

The revenues in our business segments relate to the generative 3D layering (rapid prototyping) and CNC milling shaping (rapid tooling) technologies with subsequent injection moulding as well as precision casting. Segment revenue information is presented on the basis of the domicile of the respective customer.

	Central Europe	North Europe	Not allocated	Group
T€	2009	2009	2009	2009
External revenues	4.714	794	0	5.508
Revenues with other segments	98	59	-157	0
Revenues	4.812	853	-157	5.508
Segment earnings	-607	31	-286	-862
Interest income	14	0	0	14
Interest expense	-17	-7	-50	-74
Other expenses, net	0	0	0	0
Profit/loss before taxes	-610	24	-336	-922
Income taxes	-40	0	90	50
Net result for the period	-650	24	-246	-872

	Central Europe	North Europe	Not allocated	Group
T€	2008	2008	2008	2008
External revenues	4.379	895	0	5.274
Revenues with other segments	141	60	-201	0
Revenues	4.520	955	-201	5.274
Segment earnings	185	16	0	201
Interest income	129	1	-7	123
Interest expense	-1	-8	7	-2
Other expenses, net	0	0	0	0
Profit/loss before taxes	313	9	0	322
Income taxes	-1	0	0	-1
Net result for the period	312	9	0	321

The following table shows the geographical distribution of revenues:

Consolidated revenues:

T€	Rapid Prototyping		Rapid Tooling		Precision Casting		not allocated		Total	
	2009	2008	2009	2008	2009	2008	2009	2008	2009	2008
Germany	2.239	3.038	343	613	529	0	0	0	3.111	3.651
Finland	304	380	47	50	0	0	0	0	351	430
UK	377	474	3	0	0	0	0	0	380	474
Rest of Europe	509	561	28	12	230	0	0	0	767	573
Rest of World	48	138	14	8	837	0	0	0	899	146
Total	3.477	4.591	435	683	1.596	0	0	0	5.508	5.274

Stock option plans

Stock option plan 2000

By way of resolution dated 8 June 2000, the Annual General Meeting of Alphaform AG authorised the Management Board and the Supervisory Board to issue stock options under the 2000 stock option plan, the main features of which were resolved by the Annual General Meeting. The Annual General Meeting also authorised the Management Board to determine the remaining details relating to the granting of options and the terms of exercise, subject to the approval of the Supervisory Board. Furthermore, the Annual General Meeting authorised the Management Board, with the approval of the Supervisory Board, to adjust the terms and conditions of the stock options if changes in circumstances or legislation mean that the current terms and conditions are no longer practicable. The new terms and conditions must be as close to the current version as possible.

The Management Board of Alphaform AG may grant stock options to the Company's employees and the executives and employees of its subsidiaries in line with section 15 of the German Stock Corporation Act, and the Supervisory Board of Alphaform AG may grant stock options to the members of the Management Board, within defined periods of no less than three years in each case. A total of up to 10% of issued capital may be issued in the form of stock options. For this purpose, contingent capital in the amount of €359 thousand was created by the Annual General Meeting of 8 June 2000.

The options granted are divided into two tranches. The exercise price for the first tranche amounts to 120% of the market price of the shares on the grant date, while the exercise price for the second tranche amounts to 140% of the market price on the grant date. Options from the first and second tranches may not be exercised for at least two and four years respectively. The options may only be exercised if the market price of the shares has risen by at least 20% or 40% as against the market price of the shares on the grant date of the first or second tranche respectively. All options expire six years after the respective grant date.

By way of resolution of the Annual General Meeting on 25 May 2001, the terms of the 2000 stock option plan were amended in two aspects relating to the future grant of options under the 2000 stock option plan:

The price of options issued following the entry of the amendment resolution in the commercial register is calculated on the basis of the average closing price of Alphaform's shares in Xetra trading on the Neuer Markt of Deutsche Börse AG during the last 30 trading days prior to the grant date of the subscription rights. For the first half of the options, the price to be paid on exercise is 120% of the average closing price of Alphaform's shares during the reference period. For the second half of the options, the price to be paid on exercise is 140% of the average closing price of Alphaform's shares during the reference period.

In addition, the Annual General Meeting on 25 May 2001 resolved to extend the stock option plan dated 8 June 2000 so that, if options ultimately cannot be exercised or expire, or if the beneficiaries have irrevocably waived their option rights in writing to the Company, the same number of new options may be issued in place of the old options to the group for which they originally were intended.

Stock option plan 2001

The Annual General Meeting of Alphaform AG held on 25 May 2001 authorised the Management Board and the Supervisory Board to issue options under the 2001 stock option plan, the main features of which were resolved by the Annual General Meeting. The Annual General Meeting also authorised the Management Board to determine the remaining details relating to the grant of the options and the terms of exercise, subject to the approval of the Supervisory Board. Furthermore, the Annual General Meeting authorised the Management Board, with the approval of the Supervisory Board, to adjust the terms and conditions of the stock options if changes in circumstances or legislation mean that the current terms and conditions are no longer practicable. The new terms and conditions must be as close to the current version as possible.

The Management Board of Alphaform AG may grant a total of up to 34,500 stock options to the Company's employees and the executives and employees of its subsidiaries as defined by section 15 of the German Stock Corporation Act, and the Supervisory Board of Alphaform AG may grant the Management Board up to 138,000 stock options.

The conditions in accordance with which the options under the 2001 stock option plan may be exercised are the same as those for the 2000 stock option plan following the amendments resolved by the Annual General Meeting on 25 May 2001.

A total of up to 10% of the Company's issued capital may be issued in the form of stock options under the 2000 and 2001 stock option plans. Total contingent capital of €531,820 thousand was created for this purpose. No options were granted under the 2001 stock option plan until 2003. All options issued in financial year 2001 were granted under the 2000 stock option plan. In 2003, an additional 138,000 options were granted under the 2001 stock option plan.

The Annual General Meeting held on 30 May 2003 resolved a modification to the existing 2000 and 2001 stock option plans. As a result, the Company is able to create a new method of fulfilling present and future subscription rights – subject to the consent of the respective beneficiaries.

Instead of issuing shares against the payment of the exercise prices stipulated under the terms of the respective stock option plans, this modification entitles the Company to issue a

smaller number of shares in exchange for the payment of the lowest issue price of €1.00. This gives the Company a greater degree of flexibility in the fulfilment of subscription rights.

No options for shares have currently been granted.

Related parties

There were no changes within the Management Board or the Supervisory Boards in the first quarter of 2009. Mr. Matti Paasila became the Chairman of the Supervisory Board effective 15 January 2009.

The table below provides a breakdown of the shareholdings of the Management Board and the Supervisory as of 31 March 2009:

	Position	Stock options as of 31.03.09	Shares as of 31.03.09	Percentage of share capital¹⁾
Dr. Thomas Vetter	Management Board		125,321 ²⁾	2.36
Matti Paasila	Chairman of the Supervisory Board		0	0.00
Dr. Hans J. Langer	Supervisory Board		976,659 ³⁾	18.36
Falk F. Strascheg	Supervisory Board		852,317 ⁴⁾	16.03
Total		0.00	1,954.297	36.75

1) 5,318,209 shares

2) 52,750 of which shares held by Juana Parra

3) held by LHUM Vermögensverwaltungs GmbH

4) 433,583 shares of which held by Renate Strascheg Holding GmbH;
418,734 shares of which held by Falk Strascheg Holding GmbH

As of 31 March 2009, no stock options had been issued to Management Board members and members of the Supervisory Board. Alphaform AG has not granted any loans to members of the Management Board or Supervisory Board, but it has taken on a bank guarantee at Deutsche Bank AG for a loan to Dr. Vetter of €400 thousand.

Effective 1 February 2009, Alphaform AG has a consultancy agreement with Mr. Matti Paasila for services beyond the scope of his capacity as Chairman of the Supervisory Board of Alphaform AG. Mr. Paasila will support the Company on approximately 10 – 15 compensated advisory days per year for a daily fee of €1.5 thousand with his particular expertise and his access to an international network to implement the strategic reorientation. In particular, Mr. Paasila will play an active role in generating leads, analysing and valuing businesses (due diligence) and purchase price negotiations. Mr. Paasila will also advise the Company regarding the incorporation of acquired companies into the Alphaform Group in terms of operations.

Other than this, there are currently no further consulting contracts with current or former members of the Supervisory Board.

Dr. Hans J. Langer, as a member of the Supervisory Board of Alphaform AG, is also the Chairman of the Management Board of EOS Holding AG in Krailing. EOS GmbH, a wholly owned subsidiary of EOS Holding AG, is one of Alphaform AG's largest suppliers of raw

materials with a purchasing volume which, in the first three months of 2008, totalled €233 thousand (previous year: €17 thousand).

Events after the end of the first three months

Alphaform AG has announced that it will be introducing short-time work from April 2009 on account of the difficult order situation. Other than those discussed above, no events of material importance or that could require a reassessment of Alphaform or its business arose after the first three months of 2009.

Financial Calendar 2009

10th Annual General Meeting

Date: 9 July 2009

Investor Relations

E-mail:

Phone +49 (0) 89 90 500 2-35

Fax +49 (0) 89 90 500 2-1035

Alphaform AG
Kapellenstrasse 10
85622 Feldkirchen

This report can be downloaded in English or German on the Internet.